Marker Therapeutics Inc (MRKR)

[dayneyus]

What ever the next shoe to drop, it'll have to be very solid results, making orphan drug status a likely possibility. TPIV needs market excitement and acceptance with high enough volumes to overcome shorts of from 20% to 50% of volume. Only an over whelming buy side surge can overcome this low volume trading. Its a waiting game to see what the scientist can prove or management can cook up. At these low prices it may be worth the risk to start accumulating small positions as they short this to pennies; till that next shoe drops.